September 15, 2017 H3 Biomedicine to Present New Data on H3B-6527, an FGFR4 Inhibitor, at the 2017 International Liver Cancer Association Annual Meeting Presentation to highlight pre-clinical data on H3’s Lead Solid Tumor Compound Read More
September 5, 2017 H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer Read More